Literature DB >> 26001708

A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.

J-W Kwon1, E-J Park2, S-Y Jung3, H S Sohn4, H Ryu5, H S Suh6.   

Abstract

The purpose of this study was to examine the association between bisphosphonate exposure and osteonecrosis of the jaw (ONJ) in Korean patients with osteoporosis. A nested case-control study was performed using the claims database during 2002 to 2010 provided by the National Health Insurance Service. We identified a cohort of individuals with diagnosis of osteoporosis during 2002 to 2010. Cases and controls were identified during 2004 to 2010, and the date of potential cases of ONJ was defined as the index date. Bisphosphonate exposure was evaluated during 2 y prior to the index date. The association between bisphosphonate exposure and ONJ was tested by performing a conditional logistic regression analysis for matched data, and odds ratios (ORs) with 95% confidence intervals (CIs) were presented. Subjects were classified as nonuser, recent user, past user, or continuous user, depending on the prescription of bisphosphonates in 2 periods (1 to 2 y and 0 to 1 y prior to the index date). Continuous users were defined as patients who were exposed to bisphosphonate in both periods. We also examined the impact of bisphosphonate medication compliance by measuring the cumulative duration of exposure (CDE) on the risk of ONJ. A total of 212 cases with ONJ and 2,120 controls matched by sex, age, income level, and insurance type were identified among 109,787 patients with osteoporosis out of 1,025,340 enrollees in the sample cohort. The odds of having ONJ after adjusting for patient comorbidities significantly increased in continuous users of bisphosphonates (OR, 3.9; 95% CI, 2.4 to 6.2) compared to nonusers. Increased odds of ONJ were observed as CDE increased. The adjusted OR in patients with 1.5 y < CDE ≤ 2 y prior to the index date was 7.8 (95% CI, 4.0 to 15.5) versus nonusers. Our study results support significantly increased occurrences of potential ONJ in patients with osteoporosis who were exposed to bisphosphonates compared to those without exposure. © International & American Associations for Dental Research.

Entities:  

Keywords:  Asian Continental Ancestry Group; Korea/epidemiology; bisphosphonate-associated osteonecrosis of the jaw; drug-related side effects and adverse reactions; medication compliance; retrospective studies

Mesh:

Substances:

Year:  2015        PMID: 26001708     DOI: 10.1177/0022034515587862

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  8 in total

1.  Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid.

Authors:  Akira Taguchi; Yukari Uemura; Takumi Imai; Shiro Tanaka; Hiroaki Ohta; Toshitaka Nakamura; Hajime Orimo; Toshitsugu Sugimoto; Satoshi Soen; Masataka Shiraki
Journal:  J Bone Miner Metab       Date:  2019-02-04       Impact factor: 2.626

2.  Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: a population-based nested case-control study.

Authors:  Hankil Lee; Dong-Ho Song; Jin-Won Kwon; Euna Han; Min-Jung Chang; Hye-Young Kang
Journal:  Eur Child Adolesc Psychiatry       Date:  2018-02-19       Impact factor: 4.785

3.  The utility of bone scintigraphy in the assessment of mandibular metabolism during long-term bisphosphonate administration.

Authors:  Yumiko Ohbayashi; Fumi Nakai; Akinori Iwasaki; Takaaki Ogawa; Yuka Yamamoto; Yoshihiro Nishiyama; Minoru Miyake
Journal:  Odontology       Date:  2016-10-21       Impact factor: 2.634

4.  Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China.

Authors:  Qianyu Wang; Guifang Guo; Zhaohui Ruan; Huijiao Cao; Ying Guo; Long Bai; Chang Jiang; Shousheng Liu; Wenzhuo He; Jinsheng Huang; Yuming Rong; Xuxian Chen; Liangping Xia; Bei Zhang; Roujun Peng
Journal:  J Oncol       Date:  2020-09-30       Impact factor: 4.375

Review 5.  Review and Update of the Risk Factors and Prevention of Antiresorptive-Related Osteonecrosis of the Jaw.

Authors:  Ha Young Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2021-10-21

6.  Up to 7% of referrals to oral and maxillofacial surgery are related to medication-related osteonecrosis of the jaws: how much is really out there?

Authors:  Ailish Clark; Iain Pretty
Journal:  BDJ Open       Date:  2022-02-22

7.  Dose-Intensity of Bisphosphonates and the Risk of Osteonecrosis of the Jaw in Osteoporosis Patients.

Authors:  Sung-Mok Jung; Sujeong Han; Hye-Young Kwon
Journal:  Front Pharmacol       Date:  2018-07-20       Impact factor: 5.810

8.  Gradual, but Not Sudden, Dose-Dependent Increase of ONJ Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With Osteoporosis.

Authors:  Jung-Hyun Park; Min-Jeong Kwoen; Jae-Ryun Lee; Keun-Suh Kim; Hyo-Jung Lee; Jin-Woo Kim; Hyejin Lee
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.